

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320

Status	RECRUITING
Phase	Phase 1
Sponsor	Atea Pharmaceuticals, Inc.
Enrollment	28 participants

Key Eligibility Criteria

Inclusion (13)

- Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
- Females must have a negative pregnancy test at Screening and prior to dosing
- BMI of 18.5 to 43.0 kg/m²
- Willing to comply with the study requirements and to provide written informed consent
- Renal Impaired Subjects (Group 1):
... and 8 more (see full listing online)

Exclusion (15)

- Pregnant or breastfeeding
- Infected with hepatitis B virus, hepatitis C virus or HIV
- Abuse of alcohol or drugs
- Use of other investigational drugs within 28 days of dosing
- Other clinically significant medical conditions or laboratory abnormalities
... and 10 more (see full listing online)

Locations (2 total)

Atea Study Site, Orlando, Florida, United States
Atea Study Site, Tampa, Florida, United States